Humira
Novartis to compare Cosentyx with Humira in new clinical trials
June 8, 2016Research and Development Cosentyx, Humira, Novartis, comparison, eular 2016
Novartis has announced that it plans to directly compare Cosentyx (secukinumab) versus Humira (adalimumab) in patients with ankylosing spondylitis and …
Samsung Bioepis takes AbbVie to court over attempts to delay Humira biosimilars
April 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Biogen, Humira, Samsung Bioepis, biosimilars, rheumatoid arthritis
Samsung Bioepis has filed a lawsuit against Abbvie (NYSE: ABBV) to stop the maker of the world’s bestselling drug Humira …
Sanofi says its RA drug bested Humira in Phase III study
March 11, 2016Medical Communications, Research and Development Humira, Regeneron, Sanofi
Sanofi and its R&D arm Regeneron Pharmaceuticals say their monoclonal antibody sarilumab outperformed AbbVie’s Humira in treating the symptoms of …
Top 10 medicines issued in England by prescription cost in 2014-15
March 2, 2016Research and Development, Sales and Marketing Cost, Humira, NHS, prescription
AbbVie, Humira (adalimumab), £371m. This drug treats a variety of conditions including psoriatic arthritics, Crohn’s disease and ulcerative colitis. The …
Merck begins late-stage trials of Humira biosimilar
March 2, 2016Research and Development, Sales and Marketing AbbVie, Humira, Merck, biosimilars
Merck has announced the beginning of a global phase III study of its Humira (adalimumb) biosimilar, MSB11022, in chronic plaque …
AbbVie posts strong Q4 results
February 1, 2016Sales and Marketing AbbVie, Humira, Viekira Pak
AbbVie managed to meet or beat analysts’ expectations in its Q4 financial results report, with extremely strong Humira sales contributing …
New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs
December 16, 2015Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin
NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …
Amgen’s Humira biosimilar succeeds in Phase III arthritis study
November 16, 2015Research and Development, Sales and Marketing Amgen, Humira
Amgen says its Humira (adalimumab) biosimilar candidate ABP 501 proved its clinical equivalence to Abbvie’s blockbuster drug in a head-to-head …
Lilly/Incyte RA drug bests Humira in Phase III trial
November 10, 2015Research and Development Humira, baricitinib, lilly, phase III, rheumatoid arthritis
Eli Lilly says its investigational therapy baricitinib outperformed AbbVie’s Humira after 12 weeks in a late-stage study of people with …
AbbVie reports 26% rise in Q3 revenues
October 30, 2015Sales and Marketing AbbVie, Humira
AbbVie has announced stronger-than-anticipated Q3 financial results, its revenues increasing 26.2% on the same period last year to $5.944 billion, …
AbbVie’s Humira receives first European OK for skin condition
August 3, 2015Sales and Marketing AbbVie, Hidradenitis suppurativa, Humira, adalimumab
The European Commission has approved AbbVie’s Humira as a treatment for moderate-to-severe hidradenitis suppurativa – a chronic condition affecting the …
AbbVie’s Humira meets endpoint in eye disease study
May 6, 2015Research and Development, Sales and Marketing AbbVie, FDA, Humira, Zydus Cadila, adalimumab, uveitis
In a Phase III trial AbbVie’s anti-inflammatory medicine Humira has been shown to significantly lower the risk of uncontrolled uveitis …
AbbVie buys Pharmacyclics in $21 billion deal
March 5, 2015Sales and Marketing AbbVie, Humira, Johnson and Johnson, Pharmacyclics, adalimumab, imbruvica
AbbVie has secured Californian biotech Pharmacyclics and beat Johnson & Johnson to gain control of blockbuster blood cancer therapy Imbruvica in …
Pfizer to buy Hospira for $17 billion
February 5, 2015Sales and Marketing Hospira, Humira, Pfizer, acquisition, biosimilars, merger
Pfizer has struck a deal with Hospira to acquire the company in a deal worth around $17 billion. Industry analysts …
